Ann: Therapeutic Goods Administration Registration Submitted, page-286

What you say is very true. DX companies have very long lead times as us long-termers know and we have been patient but...

Last year we were given a very clear roadmap.

Product launch was meant to have been done after getting TGA/CE/FDA approval, after all you can't sell a test until you have approval.

Good plan.

However, TGA and FDA were dropped in order to concentrate on the huge market in Europe. Fair enough. We were happy with this plan as we could come back to TGA/FDA approvals at a later date. Unknown to us, they had no sales pipeline lined up in Europe. The Israel trials sounded very promising. After all, it was the Israeli government that approached us. Surely, we'd get some sales from them as they were struggling with Covid. We had other promising leads as well but like all things ADO, when it comes time to commercialize, we fail miserably. Look at what's going on with Ellume, they can't even get that deal closed, and that's with a "friend".

When EuGeni was launched I expected to hear of at least one sales contract. In the 7 months since launch what have we sold?

On this one, the B/W's can whinge all they want because clearly ADO's commercialization strategy was flawed

Thank god we have the Abbott guy starting soon. If changes haven't already been made, he'll make them